BONE: Strengthen bone.  Treat osteoporosis, osteogenesis imperfecta, and spinal cord injury.

To strengthen bone, our approaches are to employ unique mechanical loading modalities and identify novel drug candidates.  Using loading methods such as knee loading and spine loading, we are investigating how to induce global/systemic loading effects on bone formation and bone resorption.  Also, we are searching drug candidates that strengthen bone by elevating phosphorylation of eIF2a (eukaryotic translation initiation factor 2 alpha) and attenuating stress to the endoplasmic reticulum.  The results indicate that some agents can upregulate transcription factors such as ATF4 (activating transcription factor 4) for bone formation and downregulate NFATc1 (nuclear factor of activated T-cells, cytoplasmic 1) for bone resorption.  We are applying our results to treat osteoporosis, osteogenesis imperfecta, and spinal cord injury induced bone loss.

Supported by NIH/NIAMS, DoD, CTSI, IU

CANCER: Inhibit tumor growth.  Prevent bone metastasis.

To inhibit tumor growth and prevent bone metastasis, we are developing a unique microfluidic device and novel chemotherapeutic agents.  The microfluidic device will sort and destroy highly deformable metastatic cancer cells.  Novel therapeutic agents are searched to inhibit cellular migration, invasion, and osteolytic activity through the regulation of small GTPases and various kinases and phosphatases.  We are applying these agents in pre-clinical and pilot clinical studies in breast cancer and its bone metastasis.  We are also investigating their effects on chondrosarcoma and osteosarcoma.

Supported by 100 Voices of Hope, IUPUI

CARTILAGE: Prevent joint loss.  Regenerate joint tissues.

Unlike bone, cartilage does not remodel or regenerate by itself.  We are examining the efficacy of novel drug candidates as well as gentle mechanical stimulation for prevention of cartilage loss as well as regeneration of cartilage tissue.  We are particularly interested in chemical and mechanical stimuli that suppress expression and activity of matrix metalloproteinases and stimulate expression of type II collagen and aggrecan through FAK/Pyk2 signaling.

Supported by NIH/NIAMS

BIOMECHANICS: Protect pedestrians and bicyclists from automobile accidents.

We are engaged in analysis of vehicle testing data and development of a man-machine interactive system for protecting pedestrians and bicyclists from automobile accidents.

Supported by Toyota

BIOELECTRIC DEVICE: Develop a novel multi-blot Western device.

YC Bioelectric LLC (YCB) was established in 2013 with Dr. Stanley Chien (co-founder) as a SpinUp company through IU Research and Technology Corporation.   YCB is developing a multi-blot Western device for facilitating protein analysis.

Supported by NIH/NIGMS